Bioventus agrees to nationwide contact with Aetna Medicare Advantage plans

Bioventus has agreed to a nationwide contract with Aetna Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis pain. DUROLANE, is a single-injection hyaluronic acid-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract.